Pharmacological interventions such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon like peptide-1 (GLP-1)/gastric inhibitory peptide (GIP) agonists, and finerenone reduce heart failure hospitalizations in HFpEF, but their influence on pathophysiology is still being determined [12–14]. Here, GCG is linked to heart failure.